{"id":"W4390125958","doi":"10.1016/j.jval.2023.09.391","title":"EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Tocilizumab; Adalimumab; Perspective (graphical); Medicine; Internal medicine; Computer science; Rheumatoid arthritis; Artificial intelligence","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01143665,0.00055063,0.0008459847,0.0009849089,0.0003360968,0.008031444,0.001020384,0.006595181,0.01574759],"category_scores_gemma":[0.02305712,0.0002372027,0.001678159,0.001135932,0.001776338,0.003619913,0.001413137,0.004495812,0.001489766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004442386,"about_ca_system_score_gemma":0.005739238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003178508,"about_ca_topic_score_gemma":0.002990772,"domain_scores_codex":[0.9932902,0.003590844,0.0003911329,0.0004800248,0.001617632,0.0006302104],"domain_scores_gemma":[0.9872458,0.007011741,0.001613047,0.0004566626,0.002695844,0.0009768324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004853532,0.0003447328,0.003099967,0.001812249,0.0009580478,0.0005558436,0.0002169137,0.00768477,0.004584635,0.307899,0.09096283,0.5770274],"study_design_scores_gemma":[0.001196608,0.00194222,0.01402285,0.006494454,0.001019253,0.001659807,0.0005691755,0.004382137,0.00367133,0.1339229,0.8309529,0.0001664399],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0340596,0.2487412,0.01621639,0.5477563,0.007022943,0.00009285419,0.001853579,0.0002660384,0.1439911],"genre_scores_gemma":[0.6304574,0.1343099,0.01695609,0.1692997,0.02186008,0.0001643719,0.001321489,0.0003230108,0.02530786],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01574759,"threshold_uncertainty_score":0.06048352,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1502631327678599,"score_gpt":0.3781046183827965,"score_spread":0.2278414856149366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}